Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Achieving coordinated national immunity and cholera elimination in Haiti through vaccination

View ORCID ProfileElizabeth C. Lee, Dennis L. Chao, Joseph Lemaitre, Laura Matrajt, Damiano Pasetto, Javier Perez-Saez, Flavio Finger, Andrea Rinaldo, Jonathan D. Sugimoto, M. Elizabeth Halloran, Ira M. Longini Jr., Ralph Ternier, Kenia Vissieres, Andrew S. Azman, Justin Lessler, Louise C. Ivers
doi: https://doi.org/10.1101/19011072
Elizabeth C. Lee
1Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Elizabeth C. Lee
Dennis L. Chao
2Institute for Disease Modeling, Bellevue, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Lemaitre
3Laboratory of Ecohydrology, School of Architecture, Civil and Environmental Engineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Matrajt
4Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Damiano Pasetto
3Laboratory of Ecohydrology, School of Architecture, Civil and Environmental Engineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Javier Perez-Saez
3Laboratory of Ecohydrology, School of Architecture, Civil and Environmental Engineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Flavio Finger
5Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, UK
6Department for Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Rinaldo
3Laboratory of Ecohydrology, School of Architecture, Civil and Environmental Engineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan D. Sugimoto
4Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Elizabeth Halloran
4Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
7Department of Biostatistics, University of Washington, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ira M. Longini Jr.
8Department of Biostatistics, College of Public Health and Health Professions, University of Florida, Gainesville, FL, USA
9Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ralph Ternier
10Partners In Health/Zanmi Lasante, Port-au-Prince, Haiti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenia Vissieres
10Partners In Health/Zanmi Lasante, Port-au-Prince, Haiti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew S. Azman
1Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Justin Lessler
1Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louise C. Ivers
11Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA
12Center for Global Health, Massachusetts General Hospital, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: livers@mgh.harvard.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Summary

Background Cholera was introduced into Haiti in 2010. Since, there have been over 820,000 reported cases and nearly 10,000 deaths. The year 2019 has seen the lowest reported number of cases since the epidemic began. Oral cholera vaccine (OCV) is safe and effective, but has generally not been seen as a primary tool for cholera elimination due to a limited period of protection and constrained supplies. Regionally, epidemic cholera is contained to the island of Hispaniola. Hence, Haiti may represent a unique opportunity to eliminate cholera by use of OCV.

Methods We assess the probability of elimination and the potential health impact of OCV use in Haiti by leveraging simulations from four independent modeling teams. For a 10-year projection period, we compared the impact of five vaccination campaign scenarios, differing in geographic scope, vaccination coverage, and rollout duration to a status quo scenario without vaccination. Teams used common calibration data and assumptions for vaccine efficacy and vaccination scenarios, but all other model features and assumptions were determined independently.

Findings A two-department OCV campaign proposed in Haiti’s national plan for elimination had less than 50% probability of elimination across models, and only ambitious, nationwide campaigns had a high probability of reaching this goal. Despite their low probability of elimination, two-department campaigns averted a median of 13-58% of infections across models over the five years after the start of vaccination campaigns; a nationwide campaign implemented at the same coverage and rollout duration averted a median of 58-95% of infections across models.

Interpretation Despite recent declines in cholera cases in Haiti, bold action is needed to promote elimination of cholera from the region. Large-scale cholera vaccination campaigns in Haiti offer the opportunity to synchronize nationwide immunity, providing near-term protection to the population while improvements to water and sanitation infrastructure create an environment favorable to long-term cholera elimination.

Evidence before this study We searched PubMed without language or date restrictions on October 4, 2019 for all records matching (“cholera*” AND “Haiti” AND (“vaccin*” OR “elim*”)) in any field and added one known article on the probability of elimination of cholera that was not indexed by PubMed to our review. Of 94 results, four articles were not about the cholera outbreak in Haiti or the use of cholera vaccination, and 34 were not original research articles. Fourteen articles presented research on cholera biology or cholera vaccine biology, either through discussion of Vibrio cholerae genetics, immunogenicity of oral cholera vaccine (OCV), or prospective vaccine candidate antigens. Twenty articles assessed OCV vaccine effectiveness, evaluated OCV campaign implementation or attitudes and knowledge about cholera control, or presented lessons learned on outbreak response and policy as a result of the Haiti cholera outbreak. Seven articles were about general cholera outbreak epidemiology in Haiti, and six articles were related to cholera transmission models outside our research scope.

Of the nine remaining articles, five examined the impact of potential OCV campaigns at an early time point when Haiti’s cholera outbreak still exhibited epidemic dynamics, and one other projected the impact of the OCV campaigns planned after Hurricane Matthew in 2016. Two of the articles considered prospects for cholera elimination in Haiti in 2013 and 2014 and found that further targeted interventions were needed. One final study from 2017 modeled the possibility for OCV campaigns to eliminate cholera transmission in the Ouest department within a few years.

Added value of this study Previous assessments of the impact of OCV use in Haiti occurred during early points of the outbreak when OCV campaigns were unlikely to lead to cholera elimination. Our study projects cholera transmission in Haiti with multiple years of more recent data, and directly examines prospect of cholera elimination in the status quo and under various mass OCV campaign scenarios. In bringing together results from multiple modeling teams, our study provides robust evidence about the current state of cholera transmission across Haiti and the potential impact of multiple mass OCV campaign scenarios.

Implications of all of the available evidence While 2019 has seen the lowest number of cholera cases in Haiti since the outbreak began, model simulations suggest that it may be possible for cholera transmission to persist without additional cholera control interventions.While a single two-department vaccination campaign may avert roughly 13-58% of infections with V. cholerae over a five year period, only a nationwide campaign led to a high probability of cholera elimination. Ambitious nationwide vaccination campaigns may break the cycle of endemic cholera transmission in Haiti as long-term improvements to water and sanitation infrastructure, which will limit the effects of potential re-introductions of Vibrio cholerae, are being made.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

ECL, LM, ASA, and JL (JHU) are supported by the Bill and Melinda Gates Foundation (OPP1171700). DLC acknowledges Bill and Melinda Gates for their active support of the Institute for Disease Modeling and their sponsorship through the Global Good Fund. JL (EPFL), DP, JP-S, and AR acknowledge funds provided by the Swiss National Science Foundation via the project “Optimal control of intervention strategies for waterborne disease epidemics” (200021-172578). LM, JDS, MEH, and IML are supported by the National Institutes of Health National Institute of General Medical Sciences (U54GM111274). FF acknowledges support from the Swiss National Science Foundation through the Early Postdoc Mobility Fellowship (P2ELP3_175079). LCI is supported by the National Institutes of Health National Institute of Allergy and Infectious Diseases (R01AI099243) and acknowledges Bill and Melinda Gates Foundation support for cholera control and prevention (OPP1148213). The content is solely the responsibility of the authors and does not necessarily represent the official views of any funding organization.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All teams calibrated their models to publicly available weekly department-level cholera reports of suspected cases from the Haiti Ministry of Public Health and Population (MSPP) website. All modeling teams have provided a detailed supplementary methods and results section, which are assembled collectively at the summary DOI: 10.5281/zenodo.3361800.

https://doi.org/10.5281/zenodo.3362554

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted November 02, 2019.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Achieving coordinated national immunity and cholera elimination in Haiti through vaccination
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Achieving coordinated national immunity and cholera elimination in Haiti through vaccination
Elizabeth C. Lee, Dennis L. Chao, Joseph Lemaitre, Laura Matrajt, Damiano Pasetto, Javier Perez-Saez, Flavio Finger, Andrea Rinaldo, Jonathan D. Sugimoto, M. Elizabeth Halloran, Ira M. Longini Jr., Ralph Ternier, Kenia Vissieres, Andrew S. Azman, Justin Lessler, Louise C. Ivers
medRxiv 19011072; doi: https://doi.org/10.1101/19011072
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Achieving coordinated national immunity and cholera elimination in Haiti through vaccination
Elizabeth C. Lee, Dennis L. Chao, Joseph Lemaitre, Laura Matrajt, Damiano Pasetto, Javier Perez-Saez, Flavio Finger, Andrea Rinaldo, Jonathan D. Sugimoto, M. Elizabeth Halloran, Ira M. Longini Jr., Ralph Ternier, Kenia Vissieres, Andrew S. Azman, Justin Lessler, Louise C. Ivers
medRxiv 19011072; doi: https://doi.org/10.1101/19011072

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (230)
  • Allergy and Immunology (507)
  • Anesthesia (111)
  • Cardiovascular Medicine (1256)
  • Dentistry and Oral Medicine (207)
  • Dermatology (148)
  • Emergency Medicine (283)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (537)
  • Epidemiology (10047)
  • Forensic Medicine (5)
  • Gastroenterology (500)
  • Genetic and Genomic Medicine (2481)
  • Geriatric Medicine (239)
  • Health Economics (482)
  • Health Informatics (1652)
  • Health Policy (756)
  • Health Systems and Quality Improvement (638)
  • Hematology (250)
  • HIV/AIDS (536)
  • Infectious Diseases (except HIV/AIDS) (11888)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (255)
  • Medical Ethics (75)
  • Nephrology (269)
  • Neurology (2301)
  • Nursing (140)
  • Nutrition (354)
  • Obstetrics and Gynecology (458)
  • Occupational and Environmental Health (537)
  • Oncology (1257)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (326)
  • Pediatrics (737)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2294)
  • Public and Global Health (4850)
  • Radiology and Imaging (846)
  • Rehabilitation Medicine and Physical Therapy (493)
  • Respiratory Medicine (654)
  • Rheumatology (288)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (228)
  • Surgery (271)
  • Toxicology (44)
  • Transplantation (130)
  • Urology (100)